PL1649287T3 - Ocena szczepionek zawierających adjuwanty - Google Patents

Ocena szczepionek zawierających adjuwanty

Info

Publication number
PL1649287T3
PL1649287T3 PL04739011T PL04739011T PL1649287T3 PL 1649287 T3 PL1649287 T3 PL 1649287T3 PL 04739011 T PL04739011 T PL 04739011T PL 04739011 T PL04739011 T PL 04739011T PL 1649287 T3 PL1649287 T3 PL 1649287T3
Authority
PL
Poland
Prior art keywords
antigen
solid phase
immunological activity
mixture
activity
Prior art date
Application number
PL04739011T
Other languages
English (en)
Inventor
Peter Adler Würtzen
Gitte Lund
Henrik Hugo Jacobi
Hans-Henrik Ipsen
Original Assignee
Alk Abello As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34276701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1649287(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alk Abello As filed Critical Alk Abello As
Publication of PL1649287T3 publication Critical patent/PL1649287T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL04739011T 2003-08-05 2004-07-28 Ocena szczepionek zawierających adjuwanty PL1649287T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49302003P 2003-08-05 2003-08-05
DKPA200301130 2003-08-05
EP04739011A EP1649287B1 (en) 2003-08-05 2004-07-28 Evaluation of adjuvanted vaccines
PCT/DK2004/000514 WO2005022157A1 (en) 2003-08-05 2004-07-28 Evaluation of adjuvanted vaccines

Publications (1)

Publication Number Publication Date
PL1649287T3 true PL1649287T3 (pl) 2009-04-30

Family

ID=34276701

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04739011T PL1649287T3 (pl) 2003-08-05 2004-07-28 Ocena szczepionek zawierających adjuwanty

Country Status (13)

Country Link
EP (1) EP1649287B1 (pl)
KR (1) KR101132439B1 (pl)
CN (1) CN1829917B (pl)
AT (1) ATE403867T1 (pl)
AU (1) AU2004269076B2 (pl)
CA (1) CA2532726C (pl)
DE (1) DE602004015611D1 (pl)
DK (1) DK1649287T3 (pl)
ES (1) ES2310732T3 (pl)
HK (1) HK1094036A1 (pl)
MX (1) MXPA06001382A (pl)
PL (1) PL1649287T3 (pl)
WO (1) WO2005022157A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2228656B1 (en) 2005-09-15 2013-10-23 Alk-Abelló A/S Quantification of allergens
ES2349672T3 (es) * 2005-11-24 2011-01-10 Alk-Abello A/S Procedimiento para medir la actividad enzimática de enzima alergénica adsorbida.
CA2629923C (en) 2005-11-24 2014-10-14 Alk-Abello A/S A method of measuring enzymatic activity of adsorbed allergenic enzyme
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
US9618508B2 (en) 2010-12-14 2017-04-11 Glaxosmithkline Biologicals Sa Flow cytometry analysis of materials adsorbed to metal salts
WO2013046226A2 (en) * 2011-08-04 2013-04-04 Serum Institute Of India Ltd. A novel quantification method for vaccines
CN109752560A (zh) * 2019-02-28 2019-05-14 艾棣维欣(苏州)生物制药有限公司 一种佐剂生物活性的检测方法
CN113009052A (zh) * 2021-02-22 2021-06-22 中国食品药品检定研究院 水痘减毒活疫苗中β-内酰胺类抗生素的检测方法
EP4387594A1 (en) * 2021-08-17 2024-06-26 Innovar Scientific, Inc. Vaccine assessment and compliance testing methods and systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK140815B (da) * 1975-06-10 1979-11-19 Weeke Bengt Fremgangsmåde til påvisning eller bestemmelse af antistoffer i legemsvæsker ved hjælp af kendte antigener eller til bestemmelse af antigener ved hjælp af kendte antistoffer fra legemsvæsker samt et middel til anvendelse ved udøvelse af fremgangsmåden.
SU1746318A1 (ru) * 1990-06-05 1992-07-07 Институт полиомиелита и вирусных энцефалитов Способ определени концентрации белка Е вируса клещевого энцефалита в препаратах вакцины, сорбированных на гидроокиси алюмини
CN1276093C (zh) * 2001-05-15 2006-09-20 李卫云 一种检测丙肝病毒RdRp酶的方法，和载体以及用其转化的细胞株及应用

Also Published As

Publication number Publication date
CA2532726C (en) 2013-03-12
CN1829917B (zh) 2010-08-25
KR20060126892A (ko) 2006-12-11
EP1649287A1 (en) 2006-04-26
ES2310732T3 (es) 2009-01-16
KR101132439B1 (ko) 2012-03-30
HK1094036A1 (en) 2007-03-16
CN1829917A (zh) 2006-09-06
DK1649287T3 (da) 2008-11-24
EP1649287B1 (en) 2008-08-06
WO2005022157A1 (en) 2005-03-10
AU2004269076B2 (en) 2007-09-20
ATE403867T1 (de) 2008-08-15
MXPA06001382A (es) 2006-08-25
DE602004015611D1 (de) 2008-09-18
AU2004269076A1 (en) 2005-03-10
CA2532726A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
HK1094036A1 (en) Evaluation of adjuvanted vaccines
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
HUP0303134A3 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
DE602004031017D1 (de) Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
ATE188487T1 (de) Anti-gp39 antikoerper und deren verwendungen
EP1568373A3 (en) Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
BRPI9911389B8 (pt) peptídeo de antígeno de domínio ige-ch3, conjugados de peptídeo, peptídeo sintético, composição farmacêutica compreendendo os mesmos, bem como uso do referido peptídeo ou conjugado do mesmo
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
TR200103333T2 (tr) Dayanıklığı ve biyolojik uygunluğu iyileştiren yardımcı ilaç (SBA)
CY1114047T1 (el) Νεοι φορεις εκφρασης και χρησεις αυτων
WO2005078450A3 (en) Method for the detection of early b cell populations in vaccine development
WO2004073319A3 (en) Methods and compounds for raising antibodies and for screening antibody repertoires
WO2001079274A8 (en) Tuberculosis antigens and methods of use thereof
Karbach et al. Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
NO986088D0 (no) Polypeptider med evnen til Õ danne antigenbindende strukturer med spesifisi
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
WO2004032599A3 (en) Novel immunogenic proteins of leptospira
WO1998036089A3 (de) Testkit für tuberkulosediagnose durch bestimmung von alanindehydrogenase
RU2006112203A (ru) Экспресс-тест для диагностирования болезни альцгеймера
Castric et al. Peptide epitope mapping in vaccine development: Introduction
Shimizu et al. Frequency of serological cross-reactions between Ibaraki and bluetongue viruses using the agar gel immunodiffusion test
DE69937258D1 (de) Genetische impstoffe mit adjuvans